Phenotypic Factors Associated with Amisulpride‐induced Weight Gain in First‐episode Psychosis Patients (from the OPTiMiSE Cohort)

R. Pandit,D. Cianci,S. E. ter Hark,I Winter-van Rossum,B. H. Ebdrup,B. Broberg,M. P. Garcia-Portilla,J. Bobes,C. H. Vinkers,R. S. Kahn,S. Guloksuz,A. D. R. Huitema,J. J. Luykx

DOI: https://doi.org/10.1111/acps.13074

2019-01-01

Acta Psychiatrica Scandinavica

Abstract:ObjectiveAntipsychotic‐induced weight gain (AiWG) is a debilitating adverse effect of most antipsychotics. First‐episode psychosis patients are particularly vulnerable to the detrimental consequences of AiWG. Amisulpride has good efficacy and tolerability. We here aimed to identify the phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients.MethodData were collected from the Optimization of Treatment and Management of Schizophrenia in Europe trial. Multivariable regression models with various phenotypic variables (N = 305) were performed with absolute AiWG and clinically relevant AiWG (≥7% AiWG) as outcomes.ResultsFour weeks of amisulpride treatment increased body weight from 69.7 to 72.4 kg (P < 0.001). In the regression model of absolute AiWG, unemployment (β = 0.94, P = 0.016), younger age (β = −0.07, P = 0.031) and absence of current comorbid major depression disorder (β = −1.61, P = 0.034) were positively associated with absolute AiWG. In the regression model of clinically relevant AiWG, unemployment (OR = 2.83, P = 0.001), schizophreniform disorder (OR = 2.00, P = 0.025) and low baseline weight (OR = 0.97, P = 0.032) increased the likelihood of clinically relevant AiWG.ConclusionsClinicians prescribing amisulpride should consider the relatively high susceptibility to AiWG in unemployed first‐episode patients with psychosis, in particular young subjects with a diagnosis of schizophreniform disorder. We advise to carefully monitor these patients and, when needed, implement weight‐reducing strategies.